Balchem Corporation — FY2012 Form 10-K
Business context and period. The filing covers the fiscal year ended December 31, 2012; it is an annual report, not a standalone fourth-quarter filing. Balchem develops and sells specialty ingredients and products through three segments: Specialty Products, Food, Pharma & Nutrition (FPN), and Animal Nutrition & Health (ANH). Amounts below are in U.S. dollars; financial figures are in millions unless noted.
Financial performance and liquidity
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Net sales | $310.4 | $291.9 | +6.3% |
| Gross margin | $89.5 | $86.0 | +4.1% |
| Gross margin rate | 28.8% | 29.5% | -0.7 percentage points |
| Operating earnings | $59.8 | $56.2 | +6.3% |
| Operating margin | 19.3% | 19.3% | Unchanged |
| Net earnings | $40.0 | $38.8 | +3.2% |
| Diluted EPS | $1.32 | $1.28 | +3.1% |
| Cash from operations | $53.8 | $44.9 | +19.8% |
- Segment sales / operating earnings: Specialty Products $50.0 / $20.3; FPN $44.1 / $11.3; ANH $216.3 / $28.1. ANH was the largest segment and main sales-growth contributor.
- Cash and working capital: Cash and cash equivalents were $144.7 at year-end, up from $114.8. Working capital was $181.7, versus $144.8.
- Debt and equity: No debt was outstanding at December 31, 2012, compared with $1.4 at year-end 2011. Stockholders’ equity was $273.0, up from $232.0.
- Investment and distributions: Capital expenditures were $13.9, including $7.3 for the Covington, Virginia manufacturing facility. Dividends paid were $11.7, including an accelerated $6.5 payment ($0.22 per share) ordinarily expected in early 2013.
- Fourth-quarter supplemental data (unaudited): Sales were $80.1 versus $69.7 in Q4 2011; net earnings were $9.9 versus $9.5; diluted EPS was $0.33 versus $0.31.
Material changes versus prior periods
- FY2012 sales increased 6.3%, led by ANH growth of 7.4% and Specialty Products growth of 4.5%; FPN grew 3.6%.
- ANH specialty ingredients grew 22.3%, supported by higher volumes and improved regional dairy economics. Industrial-use choline and derivatives grew 16.1%, including demand associated with oil and gas fracking.
- Feed-grade choline sales declined about 2.4% due to lower volumes; foreign currency reduced those sales by approximately $2.8 million.
- Gross margin rate declined as key raw-material costs rose and the company suspended AminoShure-L sales. Operating expenses were essentially flat year over year.
- Operating cash flow improved, while capital spending more than doubled, principally reflecting the Covington facility project. The European term loan was prepaid in full; credit facilities that matured in 2012 were not renewed.
Outlook, commentary, risks and unusual items
- Outlook: Management expected operations to generate sufficient cash for working capital and necessary investment, and projected 2013 capital expenditures of $7.0–$8.0 million. It was pursuing acquisition candidates and said borrowing or capital-market funding could be considered if needed. No formal earnings or revenue guidance was provided.
- Product suspension: Balchem suspended AminoShure-L, 52% lysine, after research found bioavailability below its original design expectations; the company reported no safety concern. Related sales credits were approximately $1.0 million, with an estimated net gross-margin impact of about $0.8 million and additional operating costs of about $0.2 million.
- Key risks: Raw-material price volatility and supply, competition and pricing pressure, dependence on manufacturing reliability, regulatory approvals and EPA pesticide registrations, product liability/recalls, international economic and currency exposure, and labor relations. Approximately 33% of FY2012 sales were outside the U.S.
- Regulatory and environmental matters: EPA registrations for ethylene oxide and propylene oxide remain important to Specialty Products; both were scheduled for EPA registration review in FY2013. The Verona, Missouri site has legacy Superfund remediation matters, with the prior owner responsible for further remedy and Balchem reporting contractual indemnification. NYDEC discussions concerning a Slate Hill site cleanup remained ongoing; monitoring had recently cost less than $5,000 annually. Management did not expect legal proceedings to have a material financial effect.
- Other items: The company reported $1.696 million of liabilities for uncertain tax positions, interest and penalties for which settlement timing could not be reasonably estimated. U.S. cash balances exceeded FDIC insurance limits effective January 1, 2013. The auditor gave an unqualified opinion on the financial statements and internal control; management also concluded controls were effective.
Important facts for investors to verify
- Whether ANH specialty-product growth and industrial-use demand can continue, and how much sales remain exposed to fracking-related activity.
- Whether the lower gross margin rate persists as raw-material costs and product mix change, and whether pricing offsets those costs.
- Whether the AminoShure-L suspension has further effects on customer relationships, sales, or product development.
- Completion, cost and expected returns of the Covington facility investment, alongside the 2013 capital-spending plan.
- Regulatory status of the ethylene oxide and propylene oxide registrations, and any developments in the Verona or Slate Hill environmental matters.
- Cash deployment and capital allocation, including acquisition activity, dividends, and the effect of the accelerated dividend on comparisons of cash flows.